|
Valoración de DCF de Xenetic Biosciences, Inc. (XBIO)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Xenetic Biosciences, Inc. (XBIO) Bundle
¿Busca evaluar el valor intrínseco de Xenetic Biosciences, Inc.? Nuestra calculadora DCF (XBIO) integra datos del mundo real con características integrales de personalización, lo que le permite ajustar los pronósticos y mejorar sus estrategias de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .4 | 1.2 | 1.7 | 2.5 | 4.4 | 7.7 | 13.4 | 23.3 | 40.5 |
| Revenue Growth, % | 0 | 2460.31 | 165.64 | 47.06 | 48.8 | 73.97 | 73.97 | 73.97 | 73.97 | 73.97 |
| EBITDA | -9.6 | -4.7 | -5.7 | -6.7 | -4.5 | -4.4 | -7.7 | -13.4 | -23.3 | -40.5 |
| EBITDA, % | -56111.35 | -1074.23 | -492.06 | -393.57 | -177.79 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | 1.0 | 1.7 | 3.0 | 5.2 | 9.0 |
| Depreciation, % | 161.06 | 6.6 | 3.06 | 1.58 | 0 | 22.25 | 22.25 | 22.25 | 22.25 | 22.25 |
| EBIT | -9.6 | -4.7 | -5.7 | -6.7 | -4.5 | -4.4 | -7.7 | -13.4 | -23.3 | -40.5 |
| EBIT, % | -56272.41 | -1080.83 | -495.12 | -395.15 | -177.79 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 10.4 | 11.5 | 18.2 | 13.1 | 9.0 | 4.4 | 7.7 | 13.4 | 23.3 | 40.5 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | .9 | .3 | .4 | .3 | .2 | 2.1 | 3.6 | 6.2 | 10.8 | 18.8 |
| Accounts Payable, % | 5456.04 | 74.93 | 31.23 | 16.83 | 9.48 | 46.49 | 46.49 | 46.49 | 46.49 | 46.49 |
| Capital Expenditure | .0 | .0 | .0 | -.5 | .0 | -.3 | -.5 | -.8 | -1.4 | -2.4 |
| Capital Expenditure, % | 0 | 0 | 0 | -29.29 | 0 | -5.86 | -5.86 | -5.86 | -5.86 | -5.86 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -12.0 | -3.7 | -5.6 | -6.6 | -4.5 | -4.2 | -7.3 | -12.7 | -22.1 | -38.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -11.0 | -4.3 | -5.6 | -7.1 | -4.6 | -1.7 | -4.5 | -7.9 | -13.7 | -23.8 |
| WACC, % | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 | 15.13 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -29.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -24 | |||||||||
| Terminal Value | -185 | |||||||||
| Present Terminal Value | -91 | |||||||||
| Enterprise Value | -121 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | -112 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -73.19 |
What You Will Get
- Real Xenetic Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Xenetic Biosciences, Inc. (XBIO).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to (XBIO).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Xenetic's fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections relevant to (XBIO).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for (XBIO).
Key Features
- Comprehensive Data Access: Xenetic Biosciences' historical financial records and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe the intrinsic value of Xenetic Biosciences recalculating instantly.
- Intuitive Visual Displays: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable resource for analysts, investors, and finance professionals.
How It Works
- 1. Download the Model: Obtain and open the Excel template featuring Xenetic Biosciences, Inc.'s (XBIO) financial data.
- 2. Adjust Key Inputs: Modify essential variables such as revenue growth, discount rates, and investment expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes the intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Evaluate various projections to understand a range of valuation possibilities.
- 5. Present with Assurance: Share professional valuation analyses to enhance your strategic decisions.
Why Choose Xenetic Biosciences, Inc. (XBIO)?
- Innovative Solutions: Pioneering advanced drug delivery technologies to enhance therapeutic outcomes.
- Proven Expertise: A dedicated team with extensive experience in biopharmaceutical development.
- Robust Pipeline: A diverse range of products in various stages of development to meet market needs.
- Commitment to Quality: Adherence to the highest standards in research and manufacturing processes.
- Collaborative Partnerships: Strong alliances with industry leaders to drive innovation and growth.
Who Should Use This Product?
- Biotechnology Students: Understand drug development processes and apply them to real-world case studies.
- Researchers: Utilize advanced models to enhance your studies in biotech innovations.
- Investors: Evaluate your investment strategies and analyze valuation metrics for Xenetic Biosciences, Inc. (XBIO).
- Market Analysts: Optimize your analysis with a comprehensive, adaptable financial model tailored for biotech firms.
- Entrepreneurs: Learn from the strategies used by established biotech companies like Xenetic Biosciences, Inc. (XBIO).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Xenetic Biosciences historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models that illustrate intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate thorough analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Xenetic Biosciences, Inc. (XBIO).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy result analysis.